Trasylol Lawyers at Anapol Schwartz | Philadelphia Pennsylvania Attorneys at Law
  Do I have a Trasylol case? ... Contact us for a free consultation with one of our Trasylol Lawyers

About Trasylol

Heart Attack Risk after Heart Surgery

Bayer Suspends Trasylol Sales November 5, 2007

Benefits of Retaining Anapol Schwartz

Do you have a Trasylol case?

pdf guide

FDA Gets Trasylol Off the Market

BART Study Enrollment Ceases due to problems with Trasylol Safety.

Trasylol Wrongful Death Complaint

Do you have a NSF lawsuit?

Web Resources

Blog

 

BART Study Suggests Problem with the Drug Trasylol TrasylolLawsuit

Contact us for a free legal consultation about your Trasylol Lawsuit


BART Study May Get Suspended

On October 19, 2007, FDA was notified of the Data Safety Monitoring Board’s (DSMB) recommendation to stop patient enrollment in the aprotinin BART study. This early termination may signal problems with the drug. Aprtinin is marketed as Trasylol by Bayer, Inc.. Trasylol is used in blood conservation during surgery. The randomized trial in a cardiac surgery population (BART) study has preliminary findings suggesting that when compared to the antifibrinolytic drugs, epsilon-aminocaproic acid and tranexamic acid, aprotinin increases the risk of death.

The study had planned to follow 3,000 adult Canadian patients who were to have heart surgery and were at a high risk for bleeding.

The interim analyses showed that the 30-day mortality in the aprotinin group was stastically significant. The increased death rate in the aprotinin patients was observed in the study. Thus, the use of aprotinin for less serious bleeding cases could be a problem in terms of risk benefit.

Once additional data is collected, analyses will assess the findings from the BART study and determine if the drug should be pulled from the market.

The FDA anticipates re-evaluation of the overall risks and benefits of Trasylol. This re-evaluation may result in the drug being pulled from the market. An alternative would be to revise the labeling. Doctors are now on notice that the benefits of this drug may not outweigh the risks in many cases. Data is mounting against Trasylol, suggesting Trasylol administration increases the risk for death compared to other antifibrinolytic drugs.

Trasylol is used for prophylactic use to reduce perioperative blood loss in the course of coronary artery bypass graft (CABG) surgery.

Do you have a Trasylol lawsuit?


Do you have a Trasylol/Aprotinin Lawsuit?

Do you need a Trasylol/aprotinin lawyer to fight for you? Do you have an unsafe aprotinin lawsuit? Isn’t it about time to consider the options?

PERSONAL INFORMATION



First Name:
Last Name:
E-mail Address:
Phone: () - ext.
Address:
City:
State:
Zipcode:
Date of birth of injured person:


TRASYLOL LAWSUIT INFORMATION

Date of surgery:
Have you (or injured party) experienced any of the following? (check all that apply)
Kidney failure
Stroke
Heart attack
Heart failure
Encephalopathy/brain disease
Death
Did you (or injured party) require dialysis? Yes No
Please describe the side effects you experienced:
Other information:

Copyright © 2004- - Anapol Schwartz - Pennsylvania Trasylol Lawyers Our Attorneys in Pennsylvania and New Jersey Trasylol Lawyers - Trasylol Class Action Law Firm. All rights reserved.

Trasylol Attorney Disclaimer:This website is dedicated to providing public information regarding Trasylol and other legal information. None of the information on this site is intended to be formal legal advice, nor the formation of a lawyer or attorney client relationship. Please contact a Pennsylvania Trasylol lawyer in Philadelphia - Ask a Trasylol attorney at our law firm for information regarding your particular case. This website is not intended to solicit clients outside the States of New Jersey, Pennsylvania, and West Virginia.